ReviewMolecular therapy. Methods & clinical development2017
Bringing Neural Cell Therapies to the Clinic: Past and Future Strategies.
Review in Molecular therapy. Methods & clinical development, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 43 citations in OpenAlex.
- Neural Stem/Progenitor Cells Regulate Neuroinflammation: Mechanisms and Therapeutic Applications in Neurological Diseases.International journal of molecular sciences · 2026Review
- Stem Cell Therapy for Post-Traumatic Stress Disorder: A Novel Therapeutic Approach.Diseases (Basel, Switzerland) · 2021Review
- Review
- MiR-140-5p targets Prox1 to regulate the proliferation and differentiation of neural stem cells through the ERK/MAPK signaling pathway.Annals of translational medicine · 2021Article
- Generation of UCiPSC-derived neurospheres for cell therapy and its application.Stem cell research & therapy · 2021Article
- Neural Progenitor Cells Alter Chromatin Organization and Neurotrophin Expression in Response to 3D Matrix Degradability.Advanced healthcare materials · 2020Article
- Cryopreservation as a Key Element in the Successful Delivery of Cell-Based Therapies-A Review.Frontiers in medicine · 2020Review
- Neurons from human mesenchymal stem cells display both spontaneous and stimuli responsive activity.PloS one · 2020Article
- Direct Conversion of Human Urine Cells to Neurons by Small Molecules.Scientific reports · 2019Article
- Matrix Remodeling Enhances the Differentiation Capacity of Neural Progenitor Cells in 3D Hydrogels.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Article
- Neural stem cell therapies and hypoxic-ischemic brain injury.Progress in neurobiology · 2019Review
- Establishment of stable iPS-derived human neural stem cell lines suitable for cell therapies.Cell death & disease · 2018Article
- Engineering molecular imaging strategies for regenerative medicine.Bioengineering & translational medicine · 2018Review
- Assessing the Efficacy of Cell Transplantation for Parkinson's Disease: A Patient-Centered Approach.Journal of Parkinson's disease · 2018Review
- Showcasing Clinical Development and Production of Cellular Therapies.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- Neuronal Transplantation for Alzheimer's Disease and Prospects for Generating Exogenic Neurons as a Source of Cells for Implantation.Cell transplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell replacement therapy in the nervous system has a rich history, with ∼40 years of research and ∼30 years of clinical experience. There is compelling evidence that appropriate cells can integrate and function in the dysfunctioning human nervous system, but the clinical results are mixed in practice. A number of factors conspire to vary patient outcome: the indication, cell source, patient selection, and team performing transplantation are all variables that can affect efficacy. Most early clinical trials have used fetal cells, a limited cell source that resists scale and standardization. Direct fetal cell transplantation creates significant challenges to commercialization that is the ultimate goal of an effective cell therapy. One approach to help scale and standardize fetal cell preparations is the expansion of neural cells in vitro. Expansion is achieved by transformation or through the application of mitogens before cryopreservation. Recently, neural cells derived from pluripotent stem cells have provided a scalable alternative. Pluripotent stem cells are desirable for manufacturing but present alternative concerns and manufacturing obstacles. All cell sources require robust and reproducible manufacturing to make nervous system cell replacement therapy an option for patients. Here, we discuss the challenges and opportunities for cell replacement in the nervous system. In this review, we give an overview of completed and ongoing neural cell transplantation clinical trials, and we discuss the challenges and opportunities for future cell replacement trials with a particular focus on pluripotent stem cell-derived therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.